TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30507022

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (iNPWT)
Number of subjects: 876

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 876
Study: 29301026

Group type: EXPERIMENTAL
Intervention: Anodal (active) cerebellar tDCS for 25 minutes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham cerebellar tDCS for 25 minutes
Number of subjects: 42
Study: 26771947

Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy (SET)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Clinical management combined with pharmacotherapy (CM+MED)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Clinical management with placebo (CM+PBO)
Number of subjects: 149
Study: 24091935

Group type: EXPERIMENTAL
Intervention: PAM Level 1 (lowest activation)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: PAM Level 2
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: PAM Level 3
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: PAM Level 1
Number of subjects: 695

Group type: COMPARATOR
Intervention: PAM Level 4 (highest activation)
Number of subjects: 695
Study: 22559139

Group type: EXPERIMENTAL
Intervention: High Vagal Regulatory Capacity (VRC) in a socially supportive context
Number of subjects: 61

Group type: COMPARATOR
Intervention: High VRC in a nonsupportive context
Number of subjects: 61

Group type: COMPARATOR
Intervention: Low VRC in either context
Number of subjects: 61
Study: 20194388

Group type: EXPERIMENTAL
Intervention: Oblique incremental technique (OIT) with Ceram X mono (CXM)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Modified incremental technique (MIT) with Ceram X mono (CXM) and SureFil (SF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oblique incremental technique (OIT) with SureFil (SF)
Number of subjects: 26
Study: 17921064

Group type: EXPERIMENTAL
Intervention: Automatic CPAP (A‐CPAP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fixed CPAP (F‐CPAP)
Number of subjects: 45
Study: 16207425

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with recombinant tissue‐type plasminogen activator (rtPA) intravenously
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy with low molecular weight heparin
Number of subjects: 24
Study: 12463459

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 0
Study: 11910672

Group type: EXPERIMENTAL
Intervention: 40‐mg isoflavone supplement (one tablet per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined values for all subjects
Number of subjects: 51
Study: 7722115

Group type: EXPERIMENTAL
Intervention: Heart failure patients (protocol 1)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control subjects (protocol 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Heart failure patients (protocol 2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control subjects (protocol 2)
Number of subjects: 29
Study: 2039897

Group type: EXPERIMENTAL
Intervention: Bladder retraining and terodiline 25 mg daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Bladder retraining and placebo
Number of subjects: 37
Study: 31444003

Group type: EXPERIMENTAL
Intervention: Precision ID Ancestry Panel (165 autosomal AIMs)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: GenoGeographer (new reference populations constructed from 75 Uyghur and 75 Kazakh individuals)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: GenoGeographer
Number of subjects: 199
Study: 30040762

Group type: EXPERIMENTAL
Intervention: Bimanual training with error augmentation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bimanual training without error augmentation
Number of subjects: 26
Study: 26578735

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 609
Study: 24561653

Group type: EXPERIMENTAL
Intervention: HIT 0.5 (1 HIT session every second week)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HIT 1 (1 HIT session per week)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 17
Study: 22332767

Group type: EXPERIMENTAL
Intervention: Spongiosum block along with intraurethral lignocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraurethral lignocaine only
Number of subjects: 50
Study: 19846114

Group type: EXPERIMENTAL
Intervention: Guided resistance training twice weekly for 4 months (team GCK)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Unchanged training schedules (team ZSC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Guided resistance training (team GCK)
Number of subjects: 46
Study: 17989121

Group type: EXPERIMENTAL
Intervention: Transbond Plus Self Etching Primer (SEP), 3M Unitek
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transbond XT, 3M Unitek
Number of subjects: 30
Study: 15928801

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg/week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo tablets (one tab/week)
Number of subjects: 90
Study: 12010205

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 198
Study: 10599727

Group type: COMPARATOR
Intervention: GH dosage group A, 4 IU/m2 day (approximately 0.045 mg/kg x day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH dosage group B, first year 4 IU/m2 x day, thereafter 6 IU/m2 x day (approximately 0.0675 mg/kg/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH dosage group C, first year 4 IU/m2 x day, second year 6 IU/m2 x day, thereafter 8 IU/m2 x day (approximately 0.090 mg/kg x day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: GH dosage group A
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH dosage group B
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GH dosage group C
Number of subjects: 68
Study: 7774515

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 or 5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril 5 or 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril with diuretics (hydrochlorothiazide or piretanide)
Number of subjects: 0
Study: 2043070

Group type: EXPERIMENTAL
Intervention: Plucking (51 eyes)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sliding displacement (51 eyes)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (left eyes)
Number of subjects: 102
Study: 6791226

Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31167601

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) present on admission
Number of subjects: 686

Group type: COMPARATOR
Intervention: Atrial fibrillation (AF) newly detected during hospital stay
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 686

Group type: COMPARATOR
Intervention: No atrial fibrillation (AF)
Number of subjects: 686
Study: 27224980

Group type: COMPARATOR
Intervention: TAU (Treatment as usual)
Number of subjects: 321

Group type: COMPARATOR
Intervention: TMC (TAU and telephone monitoring and counseling)
Number of subjects: 321

Group type: COMPARATOR
Intervention: TMC+ (TAU and TMC plus incentives for participation in telephone contacts)
Number of subjects: 321
Study: 26058405

Group type: EXPERIMENTAL
Intervention: Cold-gel packing
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral analgesics (control group)
Number of subjects: 70
Study: 22882759

Group type: EXPERIMENTAL
Intervention: 200 mg of natural progesterone
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 400 mg of natural progesterone
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 21820536

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) in a general fitness class (n=52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (Control group, n=53)
Number of subjects: 105
Study: 19803419

Group type: EXPERIMENTAL
Intervention: BNP/NT-proBNP-guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 0
Study: 17557771

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC) 50 microg salmeterol and 500 microg fluticasone propionate twice daily for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg twice daily for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15098127

Group type: EXPERIMENTAL
Intervention: Maximal isometric voluntary abduction of the shoulder joint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shoulder joint abduction angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked arm movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forcible adduction of the arm
Number of subjects: 0
Study: 11668653

Group type: EXPERIMENTAL
Intervention: Semantic interference (SI) effect trials with semantically-related distractors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lexical control distractor conditions
Number of subjects: 0
Study: 9651466

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily), clarithromycin (250 mg twice daily), and tinidazole or metronidazole (500 mg twice daily) for 1 week
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard metronidazole and bismuth combination therapies
Number of subjects: 35
Study: 7986443

Group type: EXPERIMENTAL
Intervention: Subgingival irrigation with amine fluoride-stannous fluoride gel
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 8
Study: 2637081

Group type: EXPERIMENTAL
Intervention: Dissolved cisplatin (30 mg/24 hours)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lyophilized cisplatin
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Systemic treatment with dissolved cisplatin (50 mg/die)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 133
Study: 29952696

Group type: EXPERIMENTAL
Intervention: Real-time feedback during bodyweight squats
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (sham) feedback during bodyweight squats
Number of subjects: 20
Study: 28595250

Group type: EXPERIMENTAL
Intervention: ART FILLER Universal (AFU)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ART FILLER Fine lines (AFFL)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Global Aesthetic Improvement Scale (GAIS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Collagen synthesis
Number of subjects: 61
Study: 25919966

Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (for both aspirin and celecoxib)
Number of subjects: 28
Study: 23036841

Group type: EXPERIMENTAL
Intervention: Transfer package group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 21306414

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Linagliptin 100 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19673817

Group type: EXPERIMENTAL
Intervention: Receptive music therapy programs
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo and waiting-list control groups
Number of subjects: 150
Study: 16495394

Group type: EXPERIMENTAL
Intervention: Denosumab (6, 14, or 30 mg every three months or 14, 60, 100, or 210 mg every six months)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Alendronate (70 mg once weekly)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 15525311

Group type: EXPERIMENTAL
Intervention: Topical bupivacaine (0.25%)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 135
Study: 11396195

Group type: EXPERIMENTAL
Intervention: Galactose oxidase-Schiff test
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (individuals free of malignancies)
Number of subjects: 137
Study: 9629990

Group type: EXPERIMENTAL
Intervention: Cordaflex 20 mg retard filmtablet after fasting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cordaflex 20 mg retard filmtablet after food ingestion
Number of subjects: 12
Study: 7917771

Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 10
Study: 2901784

Group type: EXPERIMENTAL
Intervention: Ranitidine or famotidine for 4-8 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ranitidine or famotidine
Number of subjects: 65
Study: 29164649

Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Smoking group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Alcohol-smoking group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (nonalcoholic and nonsmoker patients)
Number of subjects: 108
Study: 27155968

Group type: EXPERIMENTAL
Intervention: Animal-assisted activity (AAA) with a dog, 30 min sessions, twice a week for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group with treatment as usual
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Animal-assisted activity (AAA) with a dog
Number of subjects: 80
Study: 26229963

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 116

Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 116
Study: 24148575

Group type: EXPERIMENTAL
Intervention: PVRV‐NG
Number of subjects: 816

Group type: COMPARATOR
Intervention: Verorab
Number of subjects: 816
Study: 21050644

Group type: EXPERIMENTAL
Intervention: Mixture of bovine bone mineral (BBM) and autogenous cortical bone scrapings (1:4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bovine bone mineral (BBM) alone
Number of subjects: 24
Study: 18507840

Group type: EXPERIMENTAL
Intervention: Preventive home visits by non-physician health professionals (geriatric assessment, consultation, booster session)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study: 16555061

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 14517494

Group type: EXPERIMENTAL
Intervention: Melagatran 0.1-5 mg single subcutaneous doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melagatran 3 mg subcutaneous doses every 12 hours for 4 days
Number of subjects: 0
Study: 10624638

Group type: EXPERIMENTAL
Intervention: IV PCA with morphine
Number of subjects: 1338

Group type: EXPERIMENTAL
Intervention: Continuous '3-in-1' block
Number of subjects: 1338

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 1338
Study: 9183421

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with fentanyl 50 micrograms
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 33
Study: 2192374

Group type: EXPERIMENTAL
Intervention: Tone-inhibiting dynamic ankle-foot orthosis (TIAFO)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Prefabricated plastic molded ankle-foot orthosis (AFO)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 1
Study: 343913

Group type: EXPERIMENTAL
Intervention: 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether (mepitiostane) 10 mg b.i.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoxymesterone 10 mg b.i.d. (Control)
Number of subjects: 50
Study: 28351743

Group type: EXPERIMENTAL
Intervention: Treadmill training with load (5% of body weight on non-paretic ankle)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treadmill training without load (control group)
Number of subjects: 38
Study: 27259311

Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 μg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ephedrine (4 mg/min)
Number of subjects: 60
Study: 24362908

Group type: EXPERIMENTAL
Intervention: Cryotherapy using frozen gel gloves
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (non-gloved hand)
Number of subjects: 53
Study: 22650317

Group type: EXPERIMENTAL
Intervention: Aloe vera gel (5 mg applied topically three times daily for 3 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antioxidant capsules (twice daily for 3 months)
Number of subjects: 20
Study: 19250006

Group type: EXPERIMENTAL
Intervention: Ginger 250 mg capsules for 4 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 17762964

Group type: EXPERIMENTAL
Intervention: IBD‐SCAN
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PhiCal‐Test
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LEUKO‐TEST
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Hexagon OBTI
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: C‐reactive protein
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: blood leukocytes
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Calprotectin and lactoferrin
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fecal sampling feasibility
Number of subjects: 74
Study: 15726523

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous injection of amifostine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous bolus infusions of amifostine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard (once-daily) radiation therapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemotherapy with standard radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperfractionated (twice-daily) radiation therapy plus concomitant chemotherapy
Number of subjects: 0
Study: 12374270

Group type: EXPERIMENTAL
Intervention: Dental-directed, peer-assisted ST intervention
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1084
Study: 9855432

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0
Study: 7661347

Group type: EXPERIMENTAL
Intervention: 40‐cm2 fentanyl patch and a 60‐cm2 placebo patch
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 60‐cm2 fentanyl patch and a 40‐cm2 placebo patch
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 143
Study: 3295129

Group type: COMPARATOR
Intervention: Adr (60 mg/m2 IV on day 1) and DTIC (250 mg/m2 every 3 weeks)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Cyclophosphamide (500 mg/m2 on day 1)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Actinomycin D (1.2 mg/m2 on day 1)
Number of subjects: 335
Study: 31990207

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venlafaxine XR (150 mg/day)
Number of subjects: 0
Study: 29535136

Group type: EXPERIMENTAL
Intervention: Mapping-guided ablation followed by modified circumferential pulmonary vein (PV) ablation (n=41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Modified circumferential PV ablation alone (control group, n=40)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mapping-guided ablation (n=41)
Number of subjects: 81
Study: 26801067

Group type: EXPERIMENTAL
Intervention: In-bag protected morcellation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Uncontained power myoma removal
Number of subjects: 104
Study: 25641922

Group type: EXPERIMENTAL
Intervention: CLA80:20 (4 g/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 24119523

Group type: EXPERIMENTAL
Intervention: Intralesional betamethasone (1.4 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (8 mg)
Number of subjects: 59
Study: 20958852

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 231
Study: 18211495

Group type: EXPERIMENTAL
Intervention: Combined TAIL + IFN-alpha2b group
Number of subjects: 19

Group type: COMPARATOR
Intervention: TAIL-only group
Number of subjects: 19
Study: 19148563

Group type: EXPERIMENTAL
Intervention: Risedronate treatment
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 249
Study: 16366765

Group type: EXPERIMENTAL
Intervention: 10 mg Diazepam (DZ)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11564386

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily (n = 108)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Cerivastatin 0.3 mg once daily (n = 107)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 215

Group type: COMPARATOR
Intervention: Cerivastatin 0.3 mg once daily
Number of subjects: 215
Study: 9784902

Group type: EXPERIMENTAL
Intervention: Nicotinell (nicotine patches)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 106
Study: 7945141

Group type: EXPERIMENTAL
Intervention: Cued targets (Valid) in visual modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncued targets (Invalid) in visual modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued targets (Valid) in auditory modality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncued targets (Invalid) in auditory modality
Number of subjects: 0
Study: 3555877

Group type: COMPARATOR
Intervention: Normal saline IV three minutes and again immediately prior to succinylcholine
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: 0.06 mg X kg‐1 d‐tubo‐curarine (dTc) IV three minutes prior and normal saline IV immediately prior
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Normal saline IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: 0.06 mg X kg‐1 dTc IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Number of subjects: 395